LATAM Medical Device Registration: Country-by-Country Comparison Guide (2026)
A comprehensive comparison of medical device registration requirements across Latin America's six major markets — Brazil (ANVISA), Mexico (COFEPRIS), Colombia (INVIMA), Argentina (ANMAT), Chile (ISP), and Peru (DIGEMID) — covering classification, timelines, fees, pathways, and 2026 regulatory updates.
Why Latin America Matters for Medical Device Manufacturers
Latin America is one of the most dynamic regions for medical device market expansion. The LATAM medical devices market was valued at approximately $48 billion in 2025 and is projected to reach $50.78 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.79% toward an estimated $79.66 billion by 2034. This growth is driven by aging populations, expanding healthcare coverage, rising chronic disease burden, and sustained government investment in public health infrastructure.
Brazil stands as the region's largest market at approximately $12 billion (2024), followed by Mexico at over $5.5 billion. Colombia ranks third with a $1.5 billion market growing at 5.7% annually. Argentina and Chile represent significant mid-tier markets with stabilizing economies and expanding private healthcare sectors. Peru, while smaller at an estimated $633 million (2026), is growing steadily and offers an accessible entry point into the Andean region.
For manufacturers already established in the US, EU, or Asia-Pacific, LATAM presents a compelling growth opportunity -- but one that requires navigating six distinct national regulatory authorities, each with its own classification system, registration pathway, documentation requirements, and timelines. There is no single regional market authorization. Each country must be addressed individually.
This guide provides a comprehensive, side-by-side comparison of medical device registration requirements across Latin America's six major markets: Brazil, Mexico, Colombia, Argentina, Chile, and Peru. The comparison tables and strategic recommendations are designed to help regulatory affairs professionals plan efficient multi-country market entry.
LATAM Market Snapshot
The table below provides a high-level overview of the six markets covered in this guide.
| Country | Regulatory Authority | Market Size | Classification System | Typical Timeline (Class II/III) | Registration Validity | Submission Language | Local Rep Required |
|---|---|---|---|---|---|---|---|
| Brazil | ANVISA | $12B (2024) | Classes I-IV (RDC 751/2022) | 6-12 months | Indefinite (I/II); 10 years (III/IV) | Portuguese | Yes (BRH) |
| Mexico | COFEPRIS | $5.5B+ | Classes I-III | 3-6 months (30 days fast-track) | 5 years (10 years on renewal) | Spanish | Yes |
| Colombia | INVIMA | $1.5B | Classes I, IIa, IIb, III (EU-aligned) | Immediate (I/IIa); 6-8 months (IIb/III) | 10 years | Spanish | Yes (Legal Rep) |
| Argentina | ANMAT | ~$1B+ (est.) | Classes I-IV (MD); A-D (IVD) | 15-30 days (I/II); 12-15 months (III/IV) | 5 years | Spanish | Yes (AAR) |
| Chile | ISP | ~$700M (est.) | Classes I-IV | 60-75 days (I); 6-10 months (II-IV) | Based on FSC expiry | Spanish | Yes |
| Peru | DIGEMID | $633M (2026 est.) | Classes I-IV (GHTF-aligned) | 60-120 days by class | 5 years | Spanish | Yes (Local distributor) |
Key takeaway: Every LATAM country requires a local representative or distributor, and all require submissions in the local language (Portuguese for Brazil, Spanish everywhere else). Registration validity ranges from 5 years to indefinite (Chile), and timelines range from as little as 30 days to over 12 months depending on the country and device class.
Country-by-Country Overview
Brazil (ANVISA)
Brazil is the dominant medical device market in Latin America and the most complex regulatory environment in the region. The Agencia Nacional de Vigilancia Sanitaria (ANVISA) regulates medical devices under the RDC 751/2022 framework, which established a modernized risk-based classification system aligned with IMDRF principles.
Medical devices in Brazil are classified into Classes I through IV based on risk, with Class I being the lowest risk and Class IV the highest. Class I devices follow a notification pathway, which is a relatively streamlined process. Classes II through IV require full registration with ANVISA, including submission of a comprehensive technical dossier. For Class III and IV devices, BGMP (Brazil Good Manufacturing Practice) certification is mandatory -- a facility inspection by ANVISA that costs approximately $13,500 and must be renewed every 2-4 years. As of 2026, BGMP requirements are aligned with ISO 13485, and international manufacturers are expected to hold MDSAP certification.
A Brazil Registration Holder (BRH) is mandatory for all foreign manufacturers. The BRH holds the registration on behalf of the manufacturer and serves as the point of contact with ANVISA. Electrical devices additionally require INMETRO certification. The total cost for registration in Brazil, including government fees, BGMP inspection, and consulting support, typically ranges from $15,000 to $40,000 per product.
Mexico (COFEPRIS)
Mexico is the second-largest medical device market in LATAM and offers one of the most efficient registration pathways in the region, particularly for manufacturers with existing approvals from recognized reference jurisdictions. The Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) regulates medical devices under a three-class system (Classes I-III).
COFEPRIS offers three registration pathways: standard review, equivalency, and fast-track. The fast-track pathway, which became fully operational in March 2026, allows devices with prior approval from recognized reference agencies to be approved in as little as 30 business days. Recognized jurisdictions include the US, EU, Brazil, Canada, Japan, Australia, UK, Switzerland, Singapore, South Korea, China, and Russia. This makes Mexico an attractive early market for manufacturers already holding FDA clearance or CE marking.
All submissions must be in Spanish. Registrations are valid for 5 years initially, but as of January 2026, subsequent renewals are valid for 10 years -- a significant improvement reducing the administrative burden of maintaining registrations. Total project costs typically range from $10,000 to $25,000.
Colombia (INVIMA)
Colombia has built one of the most EU-aligned regulatory systems in Latin America. The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) classifies devices into Classes I, IIa, IIb, and III, directly mirroring the EU classification framework. This alignment simplifies dossier preparation for manufacturers already familiar with EU MDR requirements.
Colombia offers two pathways: an uncontrolled pathway for Class I and IIa devices, which results in automatic approval upon submission of a complete dossier, and a controlled pathway for Class IIb and III devices, which requires full technical review by INVIMA. This means Class I and IIa devices can be registered almost immediately, while IIb and III devices take 6-8 months.
A Legal Representative is mandatory for foreign manufacturers, and importers must hold a CCAA (Certificate of Storage and Conditioning). UDI-DI submission became mandatory under Resolution 1405/2022, with the deadline for Class IIa devices falling on February 9, 2026. Over 80% of medical devices in Colombia are imported, making the country heavily reliant on foreign manufacturers. The total cost per registration is notably affordable at $2,000-$3,000, making Colombia one of the most cost-effective LATAM markets.
Argentina (ANMAT)
Argentina's Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) regulates medical devices under a four-class system for medical devices (Classes I-IV) and a separate four-class system for IVDs (Classes A-D). Argentina is a significant market with a stabilizing economy and an expanding private healthcare sector.
Lower-risk devices (Classes I and II) follow a Declaration of Conformity pathway with ANMAT review in 15-30 days. Higher-risk devices (Classes III and IV) require full technical review, which takes 60-110 days of authority review time but 12-15 months in total when dossier preparation, queue time, and administrative processing are included. Argentina requires both an Authorized Representative (AAR) and a Technical Director for all registrations.
Submissions are processed through the HELENA electronic submission system. Government fees are denominated in Argentine Pesos (ARS) and range from 215,000 to 513,000 ARS (approximately $155-$360 at current exchange rates), making Argentina one of the most affordable markets in terms of direct government fees. As of 2026, ANMAT has introduced simplified approval procedures for low-risk devices (Disposicion 8799/2025), streamlined importation processes (Disposicion 4446/25), and new rules permitting refurbished device imports (Disposicion 224/2026).
Chile (ISP)
Chile's Instituto de Salud Publica (ISP) has held PAHO/WHO National Regulatory Authority Level IV status since 2016, placing it among the most mature regulatory agencies in Latin America. However, until recently, Chile's medical device regulations covered only a narrow range of products -- specifically contraceptives, gloves, needles, and syringes required mandatory registration, while most other devices could be freely imported.
This changed dramatically on March 6, 2026, when Chile published a comprehensive new decree expanding regulation to all medical devices and IVDs. The new framework introduces a full risk-based classification system (Classes I-IV), conformity verification requirements, and a structured registration process. Transition periods range from 24 to 36 months depending on device classification, giving manufacturers time to comply. This is the single most significant regulatory development in LATAM in 2026.
Devices are registered through the GICONA submission system. A local authorized representative is required for all foreign manufacturers. Registration validity is based on the Free Sale Certificate (FSC) expiry date, meaning registrations in Chile do not have a fixed expiration period. Government fees are CLP 182,232 ($190) for medical devices and CLP 536,789 ($560) for IVDs.
Peru (DIGEMID)
Peru's Direccion General de Insumos, Instrumentos y Medicamentos (DIGEMID) regulates medical devices under Law 29459, using a four-class system (I-IV) aligned with the GHTF framework and similar to EU Directive 93/42/EEC. Peru is the smallest of the six markets covered in this guide, with an estimated $633 million market in 2026, but it is growing steadily.
DIGEMID processes registrations through the VUCE (Ventanilla Unica de Comercio Exterior) electronic submission system. Review timelines are prescribed by regulation: 60 working days for Class I, 90 for Class II, and 120 for Class III and IV. A Certificate of Free Sale (CFS) from the country of origin is required, and a local distributor or representative must hold the registration. Registrations are valid for 5 years.
Government fees are modest, ranging from approximately $400 for Class I to $580 for Class IV. As of 2026, new medical device regulations are under public consultation (Resolution 734-2024-MINSA), with digital submission improvements expected. Peru represents an accessible and cost-effective entry point for manufacturers targeting the Andean region.
Side-by-Side Comparison Tables
The following tables provide detailed comparisons across all six markets. These tables are the core reference material for planning LATAM market entry.
Classification Comparison
| Feature | Brazil (ANVISA) | Mexico (COFEPRIS) | Colombia (INVIMA) | Argentina (ANMAT) | Chile (ISP) | Peru (DIGEMID) |
|---|---|---|---|---|---|---|
| Classification system | Classes I-IV | Classes I-III | Classes I, IIa, IIb, III | Classes I-IV (MD); A-D (IVD) | Classes I-IV | Classes I-IV |
| Framework alignment | IMDRF (RDC 751/2022) | National | EU-aligned | National / Mercosur | National (new 2026 decree) | GHTF / EU Directive 93/42/EEC |
| Lowest risk class | Class I | Class I | Class I | Class I | Class I | Class I |
| Highest risk class | Class IV | Class III | Class III | Class IV (MD) / D (IVD) | Class IV | Class IV |
| Number of risk tiers | 4 | 3 | 4 | 4 (MD) + 4 (IVD) | 4 | 4 |
| IVD separate classification | Yes (RDC 830/2023) | No (same classes) | Yes (under same framework) | Yes (Classes A-D) | Yes (separate under new decree) | No (same classes) |
Registration Pathways Comparison
| Country | Simplified / Notification Pathway | Standard / Full Review Pathway | Expedited / Fast-Track Pathway | Equivalency / Recognition Pathway |
|---|---|---|---|---|
| Brazil | Notification for Class I (30 days) | Full registration for Classes II-IV (6-12 months) | No formal fast-track | Recognition of reference country approvals considered in review |
| Mexico | -- | Standard review (3-6 months) | 30-day fast-track for devices with FDA/CE/other recognized approval | Equivalency route based on approval from 12 recognized jurisdictions |
| Colombia | Auto-approval for Class I/IIa (immediate) | Full review for Class IIb/III (6-8 months) | -- | -- |
| Argentina | Declaration of Conformity for Class I/II (15-30 days) | Full technical review for Class III/IV (12-15 months total) | -- | Simplified pathway leveraging Mercosur harmonization (under development) |
| Chile | Class I (60-75 days under new decree) | Classes II-IV (6-10 months under new decree) | -- | -- |
| Peru | Class I (60 working days) | Classes II-IV (90-120 working days) | -- | -- |
Timeline Comparison by Device Class
| Country | Class I / Lowest Risk | Class II / Low-Moderate Risk | Class III / High Risk | Class IV / Highest Risk |
|---|---|---|---|---|
| Brazil | ~30 days (notification) | 6-12 months (registration) | 6-12 months (registration + BGMP) | 6-12+ months (registration + BGMP) |
| Mexico | 3-6 months (standard) / 30 days (fast-track) | 3-6 months (standard) / 30 days (fast-track) | 3-6 months (standard) / 30 days (fast-track) | N/A (3-class system) |
| Colombia | Immediate (auto-approval) | Immediate for IIa / 6-8 months for IIb | 6-8 months (full review) | N/A (maps to Class III) |
| Argentina | 15-30 days | 15-30 days | 12-15 months total | 12-15 months total |
| Chile | 60-75 days (new decree) | 6-10 months (new decree) | 6-10 months (new decree) | 6-10 months (new decree) |
| Peru | 60 working days | 90 working days | 120 working days | 120 working days |
Government Fees Comparison
| Country | Class I / Lowest | Class II / Low-Moderate | Class III / High | Class IV / Highest | Additional Costs |
|---|---|---|---|---|---|
| Brazil | $1,000-$2,000 | $1,000-$6,000 | $3,000-$6,000 + BGMP ($13,500) | $3,000-$6,000 + BGMP ($13,500) | INMETRO for electrical devices; BRH fees |
| Mexico | Variable | Variable | Variable | N/A | Local representative: $3,000-$8,000/year |
| Colombia | ~$936 (COP 3,898,330) | ~$936 (I/IIa) / ~$1,059 (IIb) | ~$1,059 (COP 4,412,400) | N/A | CCAA for importers; legal representative fees |
| Argentina | ~$155 (215K ARS) | ~$155-$250 ARS equivalent | ~$250-$360 (513K ARS) | ~$250-$360 (513K ARS) | Technical Director fees; AAR fees |
| Chile | ~$190 (CLP 182,232) | ~$190 (CLP 182,232) | ~$190 (CLP 182,232) | ~$190 (CLP 182,232) | ~$560 for IVDs (CLP 536,789) |
| Peru | ~$400 | ~$460 | ~$510 | ~$580 | CFS procurement; local distributor fees |
Note: All fee amounts in USD are approximate conversions subject to exchange rate fluctuations. Argentina's ARS-denominated fees are particularly susceptible to rate changes.
Total Project Cost Comparison
| Country | Typical Total Cost Per Registration | Cost Drivers |
|---|---|---|
| Brazil | $15,000-$40,000 | BGMP inspection ($13,500), BRH, INMETRO, Portuguese translation |
| Mexico | $10,000-$25,000 | Local representative, Spanish translation, consulting |
| Colombia | $2,000-$3,000 | Lowest cost in LATAM; legal representative, CCAA |
| Argentina | $5,000-$15,000 | AAR, Technical Director, Spanish translation |
| Chile | $5,000-$15,000 | Local representative, Spanish translation, FSC procurement |
| Peru | $5,000-$10,000 | Local distributor, CFS procurement, Spanish translation |
Documentation Requirements Comparison
| Requirement | Brazil | Mexico | Colombia | Argentina | Chile | Peru |
|---|---|---|---|---|---|---|
| Free Sale Certificate (FSC/CFS) | Required | Required | Required | Required | Required | Required |
| ISO 13485 / QMS certificate | Required (BGMP or MDSAP) | Required | Required | Required | Required | Required |
| CFR / Technical file | Required | Required | Required | Required | Required | Required |
| Clinical evidence | Class III/IV | Higher-risk devices | Class IIb/III | Class III/IV | Higher-risk classes | Class III/IV |
| Labeling in local language | Portuguese mandatory | Spanish mandatory | Spanish mandatory | Spanish mandatory | Spanish mandatory | Spanish mandatory |
| UDI submission | Yes (public UDI databases) | -- | Yes (UDI-DI mandatory) | -- | -- | -- |
| Local language translation of full dossier | Portuguese | Spanish | Spanish | Spanish | Spanish | Spanish |
| Certificate of Analysis / Test reports | Required | Required | Required | Required | Required | Required |
| Post-market surveillance plan | Required | Required | Required | Required | Required (new decree) | Required |
Local Representative Requirements Comparison
| Requirement | Brazil | Mexico | Colombia | Argentina | Chile | Peru |
|---|---|---|---|---|---|---|
| Local representative type | Brazil Registration Holder (BRH) | Local representative / third-party authorized importer | Legal Representative | Authorized Representative (AAR) | Authorized representative | Local distributor/representative |
| Who holds the registration | BRH on behalf of manufacturer | Local representative | Legal Representative | AAR on behalf of manufacturer | Local representative | Local distributor |
| Can manufacturer hold registration directly | No | No (foreign manufacturers) | No (foreign manufacturers) | No (foreign manufacturers) | No (foreign manufacturers) | No (foreign manufacturers) |
| Additional in-country requirements | BGMP for Class III/IV; INMETRO for electrical | COFEPRIS-sanctioned third party for some pathways | CCAA for importers | Technical Director required | -- | -- |
| Typical annual cost | $5,000-$15,000 | $3,000-$8,000 | $2,000-$5,000 | $3,000-$8,000 | $2,000-$5,000 | $2,000-$5,000 |
2026 Regulatory Updates by Country
This section covers the most significant regulatory changes taking effect in 2026 across the six LATAM markets.
Brazil
- RDC 751/2022 fully in effect: The modernized classification and registration framework is now the governing regulation, replacing older RDC provisions.
- RDC 830/2023 for IVDs: A dedicated regulatory framework for in vitro diagnostic devices, establishing specific classification rules and requirements.
- BGMP aligned with ISO 13485: The Brazilian GMP inspection now fully aligns with ISO 13485, and ANVISA expects international manufacturers to hold MDSAP certification.
- Mandatory MDSAP for international manufacturers: International manufacturers seeking Class III/IV registration are expected to hold MDSAP certification.
- Public UDI databases: Brazil has implemented public Unique Device Identification databases for device tracking.
- 2026-2027 regulatory agenda published: ANVISA has published its regulatory agenda outlining planned changes through 2027, including streamlined borderline classification procedures.
Mexico
- 30-day fast-track operational (March 2026): The fast-track pathway for devices with approvals from 12 recognized reference jurisdictions is now fully operational, allowing approval in as little as 30 business days.
- Plan Mexico Reform: A broader regulatory modernization initiative affecting medical device registration processes.
- Article 376 implementation: Updated provisions governing the registration and importation of medical devices.
- Extended renewal validity: Subsequent registration renewals are now valid for 10 years (up from 5 years) as of January 2026, significantly reducing the administrative burden of maintaining registrations.
- New equivalency route: Expanded recognition of foreign approvals, simplifying the pathway for devices already cleared in major markets.
Colombia
- Regulatory framework revision underway: Colombia is actively revising its medical device regulatory framework, with a new decree expected to replace the current Decree 4725.
- IMDRF alignment: The revised framework is expected to further align with IMDRF principles, bringing Colombia closer to international best practices.
- UDI-DI deadline for Class IIa (February 9, 2026): The deadline for UDI-DI submission for Class IIa devices under Resolution 1405/2022 has passed, meaning all Class IIa devices now require UDI-DI compliance.
Argentina
- Simplified approval for low-risk devices (Disposicion 8799/2025): A new simplified approval pathway for Class I and II devices, reducing the administrative burden for lower-risk products.
- Streamlined importation (Disposicion 4446/25): Updated procedures simplifying the importation of registered medical devices.
- Refurbished device imports (Disposicion 224/2026): New rules permitting the importation of refurbished medical devices under specific conditions.
- Mercosur harmonization: Ongoing efforts to harmonize medical device regulations across Mercosur member states (Argentina, Brazil, Paraguay, Uruguay), which could eventually simplify multi-country registration in the Southern Cone.
Chile
- Major new decree (March 6, 2026): The single most significant regulatory development in LATAM in 2026. Chile published a comprehensive new decree expanding medical device regulation from a narrow scope (contraceptives, gloves, needles, syringes) to all medical devices and IVDs. The decree introduces:
- Full risk-based classification (Classes I-IV)
- Conformity verification requirements
- Structured registration process through GICONA
- Post-market surveillance obligations
- Transition period: 24-36 months depending on device classification, giving manufacturers time to bring existing products into compliance.
Peru
- New medical device regulations under public consultation (Resolution 734-2024-MINSA): Updated regulations are in the public consultation phase, with potential changes to classification, documentation requirements, and timelines.
- Digital submission improvements: DIGEMID is enhancing the VUCE electronic submission system to streamline the registration process.
- Market growth: Peru's medical device market is growing toward $633 million, attracting increased attention from international manufacturers.
Strategic Market Entry Considerations
Which Market to Enter First
The optimal market entry sequence depends on the manufacturer's existing regulatory approvals, device classification, budget, and commercial priorities. However, several general principles apply:
For manufacturers with FDA clearance or CE marking: Mexico should be the first target. The 30-day fast-track pathway (operational March 2026) allows devices with approvals from recognized reference jurisdictions to be registered in as little as 30 business days. The total cost of $10,000-$25,000 is moderate, and Mexico's $5.5 billion+ market provides immediate commercial returns.
For manufacturers seeking the largest market: Brazil is unavoidable. As the $12 billion market leader, Brazil offers the largest commercial opportunity in LATAM. However, the longer timeline (6-12+ months), higher cost ($15,000-$40,000), BGMP inspection requirement, and MDSAP expectation mean Brazil requires more planning and investment. Start the Brazil process early and in parallel with faster markets.
For budget-conscious market entry: Colombia is the most cost-effective LATAM market at $2,000-$3,000 per registration. Class I and IIa devices receive automatic approval, and the EU-aligned classification system simplifies dossier preparation for manufacturers with existing CE technical files. Colombia's $1.5 billion market provides meaningful commercial scale.
For a balanced regional strategy: Consider the sequence Mexico first (fast-track, 30 days), Colombia second (low cost, immediate approval for low-risk), Peru third (moderate cost, predictable timelines), Argentina fourth (moderate cost, Mercosur benefits), Chile fifth (watch the 24-36 month transition period for the new decree), and Brazil as a sustained parallel effort.
Leveraging Existing Approvals Across LATAM
One of the most important strategic advantages in LATAM is the ability to leverage existing regulatory approvals to accelerate registration in multiple countries:
- Mexico's fast-track accepts approvals from 12 recognized jurisdictions (US, EU, Brazil, Canada, Japan, Australia, UK, Switzerland, Singapore, South Korea, China, Russia). This is the broadest recognition list in LATAM.
- Colombia's EU-aligned system means CE-marking technical files can be adapted with minimal modification, reducing dossier preparation time and cost.
- Mercosur harmonization efforts between Argentina, Brazil, Paraguay, and Uruguay could eventually enable mutual recognition, simplifying multi-country registration in the Southern Cone.
- MDSAP certification is increasingly recognized across the region. Brazil explicitly expects MDSAP for international manufacturers, and other LATAM authorities are likely to follow.
Key Risks and Mitigation
- Currency volatility: Argentina's ARS-denominated fees are subject to significant exchange rate fluctuations. Budget in USD with a buffer.
- Local representative dependency: All six markets require a local representative who holds the registration. Choose representatives carefully -- switching representatives can be complex and time-consuming. The local representative relationship is one of the most important commercial decisions in LATAM market entry.
- Chile's regulatory transition: The March 2026 decree fundamentally changes Chile's regulatory landscape. Manufacturers currently selling devices in Chile without registration (which was possible for most devices prior to the decree) must plan for compliance within the 24-36 month transition period.
- Language requirements: All six markets require documentation in the local language. Portuguese translation for Brazil and Spanish translation for the other five markets represent a significant cost and timeline factor. Invest in professional regulatory translation, not general translation services.
Frequently Asked Questions
Do I need a local representative in every LATAM country?
Yes. Every LATAM market requires a local representative, authorized agent, or distributor. Foreign manufacturers cannot hold registrations directly in any of the six countries covered in this guide. The specific role varies -- Brazil requires a BRH, Colombia a Legal Representative, Argentina an AAR plus Technical Director -- but the requirement is universal. Choose representatives with established regulatory expertise, not just commercial distribution capability.
Can I use the same technical dossier across all LATAM markets?
Partially. The core technical documentation (device description, risk analysis, clinical evidence, test reports) can be substantially reused across markets. However, each country has specific administrative requirements, local language requirements, and format expectations. Colombia's EU-aligned system makes CE technical files highly transferable. Brazil's RDC 751/2022 and Mexico's COFEPRIS requirements have their own format specifications. Plan to build a modular master dossier with a country-specific administrative section for each market.
Which LATAM market has the fastest registration timeline?
Mexico, when using the fast-track pathway. Devices with prior approval from one of the 12 recognized reference jurisdictions can be registered in as little as 30 business days. Colombia is the fastest for Class I and IIa devices, which receive automatic (immediate) approval upon submission of a complete dossier. Argentina is fastest for Class I and II devices through the Declaration of Conformity pathway (15-30 days).
Which LATAM market is the most expensive for registration?
Brazil is the most expensive, primarily due to the BGMP inspection requirement ($13,500) for Class III and IV devices, the BRH requirement, INMETRO certification for electrical devices, and Portuguese translation costs. Total project costs range from $15,000 to $40,000 per registration. Colombia is the least expensive at $2,000-$3,000 per registration.
Does Chile's new 2026 decree affect devices already on the market?
Yes. The March 6, 2026 decree expands regulation to all medical devices and IVDs. Devices that were previously exempt from registration requirements (i.e., everything except contraceptives, gloves, needles, and syringes) must now be registered during the transition period. The transition period ranges from 24 to 36 months depending on device classification. Manufacturers should begin planning compliance immediately.
Is MDSAP certification accepted in LATAM?
Yes, and its importance is growing. Brazil's ANVISA explicitly expects international manufacturers seeking Class III/IV registration to hold MDSAP certification, and the BGMP inspection is now aligned with ISO 13485 (which is part of MDSAP). While other LATAM countries do not formally require MDSAP, holding it can strengthen your submission and may facilitate future harmonization efforts, particularly under Mercosur.
What is the Colombia auto-approval pathway?
Under Colombia's regulatory framework, Class I and Class IIa devices follow an "uncontrolled" pathway. When a complete dossier is submitted to INVIMA, the registration is automatically approved without substantive technical review. This results in essentially immediate registration for lower-risk devices. Class IIb and III devices follow a "controlled" pathway requiring full INVIMA review (6-8 months). This makes Colombia uniquely efficient for lower-risk device registration.
Can I use my FDA 510(k) clearance to get faster approval in LATAM?
Yes, in several markets. Mexico's fast-track pathway explicitly accepts FDA clearance (along with approvals from 11 other jurisdictions) for 30-day processing. Other LATAM authorities may consider FDA clearance as supporting evidence, though they generally still conduct their own review. Brazil does not have a formal fast-track based on FDA clearance but does consider reference country approvals as part of the review process.
How does Mercosur harmonization affect medical device registration?
Mercosur (the Southern Common Market) has been working toward regulatory harmonization for medical devices among its member states: Argentina, Brazil, Paraguay, and Uruguay. In practice, this means increasing alignment of classification systems, technical requirements, and quality standards across these countries. Argentina's 2026 regulatory updates explicitly reference Mercosur harmonization. While a single Mercosur registration does not yet exist, the trend is toward mutual recognition and reduced duplication, which could significantly simplify multi-country registration in the Southern Cone in the coming years.
What language are submissions required in?
Portuguese for Brazil and Spanish for all other markets (Mexico, Colombia, Argentina, Chile, Peru). This is a hard requirement in all six countries -- labeling, instructions for use, and key technical documents must be provided in the local language. Professional regulatory translation is a significant line item in LATAM market entry budgets. Do not rely on machine translation for regulatory submissions.
How long are registrations valid in LATAM markets?
Registration validity varies: Brazil offers indefinite validity for Class I/II (Cadastro) and 10-year validity for Class III/IV (Registro). Colombia offers 10-year validity. Mexico offers 5 years initially, extending to 10 years on subsequent renewals (as of January 2026). Argentina and Peru offer 5-year validity. Chile does not set a fixed expiration -- validity is tied to the Free Sale Certificate expiry date. Plan for renewal processes to begin 6-12 months before expiration.
Do I need to submit UDI data in LATAM?
Requirements vary. Brazil has implemented public UDI databases and requires UDI data submission. Colombia mandates UDI-DI under Resolution 1405/2022, with the Class IIa deadline having passed on February 9, 2026. Other LATAM markets do not yet have formal UDI submission requirements, but the trend is toward adoption, particularly as IMDRF alignment increases across the region.
What happens if I miss Chile's transition period under the new decree?
If a manufacturer fails to register a device during the 24-36 month transition period established by the March 6, 2026 decree, the device may no longer be legally marketed in Chile. The specific consequences will depend on the final implementing regulations, but manufacturers should treat the transition period as a hard deadline and plan registration activities accordingly. Given that most medical devices were previously unregulated in Chile, there is likely to be a large volume of registrations during the transition period, which could strain ISP's review capacity. Early submission is advisable.
Should I register in Argentina given its economic volatility?
Despite macroeconomic challenges, Argentina remains a significant medical device market with expanding private healthcare and a stabilizing economy. Government fees are among the lowest in LATAM when converted to USD ($155-$360). The main risks are currency-related fee changes and importation logistics. Argentina's simplified approval pathways for low-risk devices (Disposicion 8799/2025) and streamlined importation rules (Disposicion 4446/25) are positive developments. For manufacturers targeting the Southern Cone, Argentina complements Brazil well, and Mercosur harmonization could yield long-term efficiencies.